• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Cardiol Therapeutics Inc.

    5/14/26 7:37:45 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRDL alert in real time by email
    6-K 1 cardiol6k.htm FORM 6-K

     

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of May 2026

    Commission File Number: 001-40712

    Cardiol Therapeutics Inc.
    (Translation of registrant's name into English)

    602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
    (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

    [   ] Form 20-F     [X] Form 40-F

     

     

     
     

     

    SUBMITTED HEREWITH

    Exhibits

    Exhibit   Description
         
    99.1   News Release dated May 14, 2026 - Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      CARDIOL THERAPEUTICS INC.
      (Registrant)
         
    Date: May 14, 2026 By: /s/ Christopher Waddick
        Christopher Waddick
      Title: Chief Financial Officer

     

     

    Get the next $CRDL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRDL

    DatePrice TargetRatingAnalyst
    6/2/2025$9.00Buy
    H.C. Wainwright
    1/28/2025$7.00Buy
    Rodman & Renshaw
    6/26/2024$10.00Buy
    ROTH MKM
    4/22/2024$9.00Buy
    H.C. Wainwright
    12/17/2021$8.00Overweight
    Cantor Fitzgerald
    12/3/2021$8.00Buy
    Canaccord Genuity
    More analyst ratings

    $CRDL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Cardiol Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $9.00

    6/2/25 8:50:52 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rodman & Renshaw initiated coverage on Cardiol Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $7.00

    1/28/25 7:11:43 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ROTH MKM initiated coverage on Cardiol Therapeutics with a new price target

    ROTH MKM initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $10.00

    6/26/24 8:07:20 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRDL
    SEC Filings

    View All

    SEC Form 6-K filed by Cardiol Therapeutics Inc.

    6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)

    5/26/26 8:58:20 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Cardiol Therapeutics Inc.

    SCHEDULE 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)

    5/15/26 4:29:22 PM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Cardiol Therapeutics Inc.

    6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)

    5/14/26 7:37:45 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRDL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

    TORONTO, May 14, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ in New York, NY, on May 19, 2026, at 1:30 p.m. EDT. A live webcast of the Fireside Chat will be accessible under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/eve

    5/14/26 7:27:00 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

    Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, which recently surpassed 75% enrollment.TORONTO, ON, May 7, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that the results from its Phase II study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the Journal of the American Heart Association ("JAHA").

    5/7/26 7:27:00 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

    Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia University–NewYork-Presbyterian, NYU Langone Health, Lenox Hill Hospital/Northwell Health, and Houston Methodist Hospital.Growing interest in MAVERIC is expected to support the activation of up to seven additional U.S. clinical centers, with the total number anticipated to reach 25.Patient enrollment surpassed 50% in early January and has now reached 75%.Target recruitment is anticipated by the end of Q2 2026, with the potential to extend into Q3 to accommodate patient enrollment from the additional clinical sites.MAVERIC builds on pos

    4/28/26 7:27:00 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRDL
    Financials

    Live finance-specific insights

    View All

    New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

    Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis.Results provide clinical evidence that CardiolRx™ reduces inflammation-driven structural damage in the heart, an important cause of heart failure progression.The ARCHER data strengthen the scientific and clinical rationale for Cardiol's lead Phase III program in recurrent pericarditis (MAVERIC) and support broader development across inflammatory cardiac conditions.Chronic inflammation is a central driver of adverse cardiac remodeling and heart failure, yet there are currently n

    12/1/25 7:27:00 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

    The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume and a significant reduction in left ventricular mass.The Company will host a webcast conference call on December 1, 2025, to discuss the ARCHER findings and their significance, and to highlight the positive implications for Cardiol's programs in inflammatory heart disease.Toronto, Ontario--(Newsfile Corp. - November 5, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company

    11/5/25 7:45:00 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRDL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cardiol Therapeutics Inc.

    SC 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)

    11/6/24 2:59:55 PM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cardiol Therapeutics Inc. (Amendment)

    SC 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)

    2/13/24 1:01:41 PM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cardiol Therapeutics Inc. (Amendment)

    SC 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)

    2/14/23 11:52:10 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRDL
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

    Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on May 28, 2025. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in the Company's Management Information Circular dated April 10, 2025.Resolutions proposed and approved at the AGM were:The election of the following directors for the ensuing year: Jennifer Chao, David E

    5/29/25 7:27:00 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

    Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual general and special meeting of shareholders (the "Meeting") held virtually via live audio webcast, on June 26, 2024. Shareholders voted in favour of all management resolutions proposed in the Company's management information circular dated May 13, 2024.Resolutions proposed and approved at the Meeting were:The election of the following directors for the

    6/27/24 12:29:00 PM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiol Therapeutics Reports Results of 2023 Annual General Meeting

    Oakville, Ontario--(Newsfile Corp. - June 29, 2023) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast, on June 28, 2023. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular. Resolutions proposed and approved at the AGM were:The election of the following directors for the ensuing year: David Elsley, Peter Pekos, Dr. Gui

    6/29/23 10:19:00 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care